-
Deep Dive into Targeted Therapies: Understanding IDH1-Mutant AML Treatments [Podcast]
02 Jul 2025 13:04 GMT
… therapy. Expert faculty also address treatment sequencing strategies, considerations for … #47;research support from: Celgene, Geron, Kura, Novartis, Otsuka, Shattuck … [package insert]. Boston, MA: Servier Pharmaceuticals LLC; 2023. Available from: https …
-
Advancing AML Treatment: Evidence-Based Regimens and Guideline Updates for Targeted Treatments in R/R AML [Podcast]
02 Jul 2025 13:04 GMT
… & Targeted Treatments.” This episode, Advancing AML Treatment: Evidence-Based … Epizyme, Faron, Fibrogen, Genentech, Geron, Gilead, GlaxoSmithKline, Glycomimetics, Hikma, … #47;bloodadvances.2022009411
16. Rigel Pharms (2022) REZLIDHIA™ (olutasidenib) …
-
New Drugs, New Decisions: How Pharmacists Are Guiding the Future of Hematologic Care
20 Jun 2025 00:56 GMT
… new drugs like imetelstat [Rytelo; Geron Corporation] in both the frontline and … therapeutic advances currently shaping the treatment of hematologic disorders such as … time.
Pharmacy Times: What challenges still persist in the treatment of hematologic …
-
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18 Jun 2025 20:24 GMT
Geron Corporation (Nasdaq: GERN), a commercial … to continued employment with Geron through the applicable vesting dates … under the plan.
About Geron
Geron is a commercial-stage biopharmaceutical … the European Union for the treatment of certain adult patients …
-
Geron Corp. Posts Narrower Loss In Q1
07 May 2025 19:15 GMT
Geron Corp. (GERN) posted a first quarter … .
As of March 31, 2025, Geron had approximately $457.5 million …
-
Geron Announces Presentations at ASCO and EHA Underscoring RYTELO® (imetelstat) Efficacy and Safety Across Range of LR-MDS Patients, and Showcasing Momentum of Myelofibrosis Program
28 May 2025 12:46 GMT
Geron Corporation (Nasdaq: GERN), a … patients regardless of prior treatment with luspatercept or lenalidomide. … levels, or their treatment history; (iv) Geron’s beliefs that the … Geron is successful in commercializing RYTELO (imetelstat) for the treatment …
-
Is Geron Corp. (NASDAQ:GERN) the Most Promising Penny Stock According to Analysts?
18 Apr 2025 16:01 GMT
… see more details here). Is Geron Corp. (NASDAQ:GERN) the Most … telomerase inhibitor for the treatment of adult patients with … received a Category 1 treatment recommendation for second-line … Hims & Hers and Geron Corporation (NASDAQ:GERN). Overall, GERN …
-
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 May 2025 20:26 GMT
Geron Corporation (Nasdaq: GERN), a commercial … to continued employment with Geron through the applicable vesting dates … under the plan.
About Geron
Geron is a commercial-stage biopharmaceutical … the European Union for the treatment of certain adult patients …
-
Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments
31 Mar 2025 20:52 GMT
… 's strategic direction.
yevtony Geron Corporation (NASDAQ:GERN) has only reported …
-
GERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Geron Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
16 May 2025 01:00 GMT
… is investigating potential claims against Geron Corporation (NASDAQ: GERN) on behalf … board of directors of Geron have breached their fiduciary … other things, confidence in Geron's ability to … a long-term stockholder of Geron, have information, would …
About
© 1995-2025